CANADA: Zenabis, a licensed producer, has announced that Health Canada has issued an amendment to its Producer’s License. Zenabis is now eligible to sell clones to other licensed producers under current Access to Cannabis for Medical Purposes Regulations (ACMPR). The amended license also opens the door for the Company to meet national demand for high-quality cannabis.
The amended sales license was issued for Zenabis’ 380,000 square foot facility in Atholville, New Brunswick, and is effective from April 13, 2018 through January 19, 2021. Zenabis received its cultivation license for Atholville in August 2017, and has since been growing top of the line, high-yielding, pharmaceutical-grade cannabis plants and preparing for its release of top quality cannabis strains.
“Obtaining our license to sell cannabis plants is a significant milestone for Zenabis and an incredible opportunity for innovation,” stated Kevin Coft, CEO of Zenabis, “We take pride in the quality and craftsmanship of our cannabis plants and with this amended license can now support the Canadian cannabis community.”
This amended license brings the Company one step closer to increasing its global presence as the prominent industry leader in cannabis innovation, production, and distribution of high-demand cannabis strains.